Mark L Heiman

US Patent:

6638936, Oct 28, 2003

Filed:

May 6, 2002

Appl. No.:

10/031310

Inventors:

Karin Briner - Indianapolis IN
Timothy Paul Burkholder - Carmel IN
Mark Louis Heiman - Indianapolis IN
David Lloyd Garver Nelson - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31496

US Classification:

51425411, 544376

Abstract:

The present invention provides serotonergic benzofurans of Formula I: where R is methyl or ethyl, or pharmaceutically acceptable acid addition salts thereof.

US Patent:

6639076, Oct 28, 2003

Filed:

Apr 17, 2001

Appl. No.:

09/762529

Inventors:

Kenneth Lee Hauser - Greencastle IN
Jeffrey Alan Dodge - Indianapolis IN
Mark Louis Heiman - Indianapolis IN
Scott Alan Jones - Indianapolis IN
Charles Arthur Alt - Greenwood IN
Henry Uhlman Bryant - Indianapolis IN
James Densmore Copp - Greenwood IN
William Harlan Gritton - Zionsville IN
Brian Stephen Muehl - Indianapolis IN
Alan David Palkowitz - Carmel IN
Andrew Michael Ratz - Greenwood IN
Gary Anthony Rhodes - Indianapolis IN
Roger Lewis Robey - Greenwood IN
Timothy Alan Shepherd - Indianapolis IN
Kenneth Jeff Thrasher - Indianapolis IN
William George Trankle - Southport IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D40112

US Classification:

546210, 514 16, 514 18, 514 19, 514222, 5142312, 514249, 514255, 514315, 514396, 514397, 530331, 546207, 546208, 546209, 546212, 5483001, 5483111, 5483147, 5483151, 5483157

Abstract:

This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.

US Patent:

6992097, Jan 31, 2006

Filed:

Jun 3, 2003

Appl. No.:

10/453833

Inventors:

Kenneth Lee Hauser - Greencastle IN, US
Jeffrey Alan Dodge - Indianapolis IN, US
Mark Louis Heiman - Indianapolis IN, US
Scott Alan Jones - Indianapolis IN, US
Charles Arthur Alt - Greenwood IN, US
Henry Uhlman Bryant - Indianapolis IN, US
Jeffrey Daniel Cohen - Indianapolis IN, US
James Densmore Copp - Greenwood IN, US
Kennan Joseph Fahey - Indianapolis IN, US
William Harlan Gritton - Zionsville IN, US
Louis Nickolaus Jungheim - Indianapolis IN, US
Joseph Henry Kennedy - Noblesville IN, US
Brian Stephen Muehl - Indianapolis IN, US
Alan David Palkowitz - Carmel IN, US
Andrew Michael Ratz - Greenwood IN, US
Gary Anthony Rhodes - Indianapolis IN, US
Roger Lewis Robey - Greenwood IN, US
David Edward Seyler - Greenfield IN, US
Timothy Alan Shepherd - Indianapolis IN, US
Kenneth Jeff Thrasher - Indianapolis IN, US
William George Trankle - Southport IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/415
C07D 233/44

US Classification:

514398, 5483265

Abstract:

This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.

US Patent:

20030073621, Apr 17, 2003

Filed:

Apr 2, 2001

Appl. No.:

09/824438

Inventors:

John Hale - Fishers IN, US
Mark Heiman - Indianapolis IN, US
Brigitte Schoner - Monrovia IN, US
Jon Butler - Pendleton IN, US
William Heath - Fishers IN, US
Gerald Becker - Fishers IN, US
Alexander Varshavsky - Carmel IN, US

International Classification:

A61K038/17
C07K014/435

US Classification:

514/012000, 530/324000, 530/333000

Abstract:

The invention provides isolated nucleic acids, vectors, transformed host cells, analogs, functional fragments, and fusion proteins, related to beta-lipotropin. Also provided are pharmaceutical compositions comprising beta-lipotropin or fragments and/or analogs thereof, and methods for treating diabetes and complications associated therewith by administration of an effective amount of beta-lipotropin.

US Patent:

20030211967, Nov 13, 2003

Filed:

Oct 18, 2002

Appl. No.:

10/258259

Inventors:

Henry Bryant - Indianapolis IN, US
Mark Heiman - Indianapolis IN, US

International Classification:

G01N033/53
A61K039/395

US Classification:

514/002000, 424/130100, 435/007100

Abstract:

The present invention provides a method selectively inhibiting ghrelin activity to treat a variety of diseases including obesity and related disorders, particularly in individuals who are genetically predisposed. One aspect of the invention comprises administering an agent that effectively neutralizes ghrelin. Another aspect comprises administering a ghrelin receptor (growth hormone secretagogue receptor) antagonist.

US Patent:

20050201938, Sep 15, 2005

Filed:

Apr 15, 2005

Appl. No.:

11/106899

Inventors:

Henry Bryant - Indianapolis IN, US
Mark Heiman - Indianapolis IN, US

International Classification:

C12Q001/00
A61K049/00
A61K038/17

US Classification:

424009200, 435004000, 514012000

Abstract:

The present invention provides a method selectively inhibiting ghrelin activity to treat a variety of diseases including obesity and related disorders, particularly in individuals who are genetically predisposed. One aspect of the invention comprises administering an agent that effectively neutralizes ghrelin. Another aspect comprises administering a ghrelin receptor (growth hor- mone secretagogue receptor) antagonist.

US Patent:

20050277677, Dec 15, 2005

Filed:

May 17, 2005

Appl. No.:

11/130766

Inventors:

Mark Heiman - Indianapolis IN, US
Dana Sindelar - Indianapolis IN, US

International Classification:

A61K031/454
A61K031/4178
A61K031/4172

US Classification:

514326000, 514397000, 514400000

Abstract:

The present invention relates to a method comprising administering to a patient diagnosed as being in need of treatment for nausea, emesis, or symptoms associated therewith comprising administering to a patient in need thereof a compound of formula (I) wherein: Ris CHCHOCH—, CH(CH)— or indol-3-ylmethyl; Y is pyrrolidinyl, 4-methyl-piperidinyl or NRR; Rare each independently C-Calkyl; Ris 2-napthyl or phenyl para-substituted by W; W is H, F, CF, C-Calkoxy or phenyl; and Ris H or CH; or a pharmaceutically acceptable salt or solvate thereof, in an amount that is effective in treating nausea, emesis, or symptoms associated therewith in said patient.

US Patent:

20060233788, Oct 19, 2006

Filed:

Sep 2, 2004

Appl. No.:

10/568467

Inventors:

Mark Heiman - Indianapolis IN, US
Kristine Kikly - Fortville IN, US
Joseph Manetta - Indianapolis IN, US
Derrick Witcher - Fishers IN, US

International Classification:

A61K 39/395

US Classification:

424133100, 530388100

Abstract:

Monoclonal antibodies, including humanized and chimeric antibodies, that bind acylated and unacylated human ghrelin are provided. Such monoclonal antibodies can be full-length, or an antigen-binding portion thereof, and are useful for neutralizing ghrelin activity, e.g., in a human subject suffering from a disorder in which ghrelin activity is detrimental.